Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
about
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study.The use of capecitabine in daily practice: a study on adherence and patients' experiencesEconomic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.Role of capecitabine in treating metastatic colorectal cancer in Chinese patients.Direct medical costs of care for Chinese patients with colorectal neoplasia: a health care service provider perspective.The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer.Efficacy, Safety, and Cost of Therapy of the Traditional Chinese Medicine, Catalpol, in Patients Following Surgical Resection for Locally Advanced Colon Cancer.Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
P2860
Q33398998-70B584DC-4735-40EB-A426-5AC4C1C0A6A1Q34459359-EB01414D-B718-42DC-A4CB-642991B18F26Q36358178-391E0993-DA9E-4D4F-8D8A-496893813255Q37327850-EC2771E0-F7B8-4F23-8D5C-F8486F1E3391Q37692395-C1DFCAE9-71AF-4AC4-A2A6-C73B2CA41109Q37960119-F5DB4911-C3E4-434D-9AD5-DDAC483C8FFCQ38473718-50D29D4A-B88A-4259-AE2A-F32441DE6721Q38918414-7B25EA21-1C9A-461B-A882-D17349E84C2EQ41195992-77A4975F-3864-43FA-A47D-116668D938B2Q43480717-818A69AA-FF36-452E-8B7F-DFEB8334BB58Q55007703-DCAB6CEF-5A7A-444E-9FDF-57FCCDBC18F5Q55025617-06615A61-6EF9-4CAC-9B74-FDF43D19EFC4Q55403954-0B850BA5-64DE-4159-A335-3EF8A4F77BE5
P2860
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@ast
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@en
type
label
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@ast
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@en
prefLabel
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@ast
Cost-analysis of XELOX and FOL ...... ision-making on reimbursement.
@en
P2093
P2860
P356
P1433
P1476
Cost-analysis of XELOX and FOL ...... cision-making on reimbursement
@en
P2093
Anne W M Lee
Daniel T T Chua
Sarah M McGhee
Vicki C Tse
Victor Lee
P2860
P2888
P356
10.1186/1471-2407-11-288
P407
P50
P577
2011-07-09T00:00:00Z
P5875
P6179
1011064742